Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial
This trial in 1200 JE-vaccination naïve children (age 12–18 mo) in Thailand and the Philippines aimed to demonstrate consistency of three successive industrial scale manufacturing lots of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and consistency between industrial scale ma...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2012-07-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.4161/hv.20071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850248576422117376 |
|---|---|
| author | Emmanuel Feroldi Chitsanu Pancharoen Pope Kosalaraksa Veerachai Watanaveeradej Kerdpanich Phirangkul Maria R. Capeding Mark Boaz Sophia Gailhardou Alain Bouckenooghe |
| author_facet | Emmanuel Feroldi Chitsanu Pancharoen Pope Kosalaraksa Veerachai Watanaveeradej Kerdpanich Phirangkul Maria R. Capeding Mark Boaz Sophia Gailhardou Alain Bouckenooghe |
| author_sort | Emmanuel Feroldi |
| collection | DOAJ |
| description | This trial in 1200 JE-vaccination naïve children (age 12–18 mo) in Thailand and the Philippines aimed to demonstrate consistency of three successive industrial scale manufacturing lots of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and consistency between industrial scale manufacturing lots and a fourth, development lot. Children received JE-CV from one of three successive industrial scale lots produced in Thailand (n = 899), or from a fourth development lot produced in the USA (n = 199), or hepatitis A control vaccine (n = 102). Antibodies were assessed by 50% plaque reduction neutralization test (PRNT50) at screening and Day 28. Seroconversion rates (titer of < 10 at baseline and ≥ 10 on Day 28, or a four-fold rise from a baseline titer of ≥ 10) were determined per group. Lot-to-lot consistency of seroconversion rate and GMT was demonstrated between the 3 industrial scale lots, and between these lots and the US lot. Seroconversion rate on pooled data 28 d after JE-CV vaccination (Thai lots) was 95.0% [95% confidence interval (CI); 93.3–96.3]. The safety profile of JE-CV was favorable and comparable with hepatitis A vaccine. There were no serious adverse events related to vaccination. This study demonstrated the consistency of three successive industrial scale JE-CV vaccine lots, as well as consistency with a development lot. The study also demonstrated that a single dose of JE-CV is well tolerated and elicits a high protective immune response, seroconverting 95% of JE-naïve Asian children aged 12–18 mo. ClinicalTrials.gov: NCT00735644 |
| format | Article |
| id | doaj-art-4faa7e5ccf0244a9b340d73787cd885f |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2012-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-4faa7e5ccf0244a9b340d73787cd885f2025-08-20T01:58:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2012-07-018792993710.4161/hv.20071Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trialEmmanuel Feroldi0Chitsanu Pancharoen1Pope Kosalaraksa2Veerachai Watanaveeradej3Kerdpanich Phirangkul4Maria R. Capeding5Mark Boaz6Sophia Gailhardou7Alain Bouckenooghe8Sanofi Pasteur Clinical Development Department; Marcy l’Etoile, FranceChulalongkorn Hospital; Bangkok, ThailandSrinagarind Hospital, Khon Kaen University; Khon Kaen, ThailandDepartment of Pediatrics, Phramongkutklao Hospital; Bangkok, ThailandDepartment of Pediatrics, Phramongkutklao Hospital; Bangkok, ThailandResearch Institute for Tropical Medicine; Mutinlupa City, PhilippinesSanofi Pasteur Global Clinical Immunology Department; Swiftwater, PA USASanofi Pasteur Global Pharmacovigilance and Epidemiology Department; Lyon, FranceSanofi Pasteur Clinical Development Department; SingaporeThis trial in 1200 JE-vaccination naïve children (age 12–18 mo) in Thailand and the Philippines aimed to demonstrate consistency of three successive industrial scale manufacturing lots of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and consistency between industrial scale manufacturing lots and a fourth, development lot. Children received JE-CV from one of three successive industrial scale lots produced in Thailand (n = 899), or from a fourth development lot produced in the USA (n = 199), or hepatitis A control vaccine (n = 102). Antibodies were assessed by 50% plaque reduction neutralization test (PRNT50) at screening and Day 28. Seroconversion rates (titer of < 10 at baseline and ≥ 10 on Day 28, or a four-fold rise from a baseline titer of ≥ 10) were determined per group. Lot-to-lot consistency of seroconversion rate and GMT was demonstrated between the 3 industrial scale lots, and between these lots and the US lot. Seroconversion rate on pooled data 28 d after JE-CV vaccination (Thai lots) was 95.0% [95% confidence interval (CI); 93.3–96.3]. The safety profile of JE-CV was favorable and comparable with hepatitis A vaccine. There were no serious adverse events related to vaccination. This study demonstrated the consistency of three successive industrial scale JE-CV vaccine lots, as well as consistency with a development lot. The study also demonstrated that a single dose of JE-CV is well tolerated and elicits a high protective immune response, seroconverting 95% of JE-naïve Asian children aged 12–18 mo. ClinicalTrials.gov: NCT00735644https://www.tandfonline.com/doi/10.4161/hv.20071safetychildrenimmunogenicityJapanese encephalitis vaccinephase 3 trial |
| spellingShingle | Emmanuel Feroldi Chitsanu Pancharoen Pope Kosalaraksa Veerachai Watanaveeradej Kerdpanich Phirangkul Maria R. Capeding Mark Boaz Sophia Gailhardou Alain Bouckenooghe Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial Human Vaccines & Immunotherapeutics safety children immunogenicity Japanese encephalitis vaccine phase 3 trial |
| title | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial |
| title_full | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial |
| title_fullStr | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial |
| title_full_unstemmed | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial |
| title_short | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial |
| title_sort | single dose live attenuated japanese encephalitis vaccine in children aged 12 18 months randomized controlled phase 3 immunogenicity and safety trial |
| topic | safety children immunogenicity Japanese encephalitis vaccine phase 3 trial |
| url | https://www.tandfonline.com/doi/10.4161/hv.20071 |
| work_keys_str_mv | AT emmanuelferoldi singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial AT chitsanupancharoen singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial AT popekosalaraksa singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial AT veerachaiwatanaveeradej singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial AT kerdpanichphirangkul singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial AT mariarcapeding singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial AT markboaz singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial AT sophiagailhardou singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial AT alainbouckenooghe singledoseliveattenuatedjapaneseencephalitisvaccineinchildrenaged1218monthsrandomizedcontrolledphase3immunogenicityandsafetytrial |